Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Trailing Twelve Months EPS: $5.06
2024 EPS Estimate: ($1.14)
2025 EPS Estimate: ($1.25)
- Current Stock Price
- $11.27
- P/E Ratio
- 2.2
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 9 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $17.39 (54.3% Upside)
